Her-2 DNA versus cell vaccine: Immunogenicity and anti-tumor activity

Cancer Immunology, Immunotherapy

Volumn 58, Issue 5, 2009, Pages 759-767

  Whittington, Paula J ^a   Radkevich Brown, Olga ^a   Jacob, Jennifer B ^a   Jones, Richard F ^a   Weise, Amy M ^a   Wei, Wei Zen ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer vaccine; DNA vaccine; Her 2; Neu

Indexed keywords

CELL VACCINE; DNA VACCINE; EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR3 ANTIGEN; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; DNA IMMUNIZATION; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; ANTIGEN PRESENTATION; CANCER VACCINES; CELL LINE, TUMOR; FEMALE; GENES, ERBB-2; GLYCOPROTEINS; HLA-DR ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ACTIVE; INTERFERON-GAMMA; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; OVARIAN NEOPLASMS; RATS; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 61349122642     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-008-0599-x     Document Type: Article

References (35)

1. P Christadoss M Poussin C Deng 2000 Animal models of myasthenia gravis Clin Immunol 94 75 87
2. BJ Czerniecki RE Roses GK Koski 2007 Development of vaccines for high-risk ductal carcinoma in situ of the breast Cancer Res 67 6531 6534
3. RR de Vries TW Huizinga RE Toes 2005 Redefining the HLA and RA association: to be or not to be anti-CCP positive J Autoimmun 25 Suppl 21 25
4. ML Disis KH Grabstein PR Sleath 1999 Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine Clin Cancer Res 5 1289 1297
5. A Dols JW Smith SL Meijer 2003 Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results Hum Gene Ther 14 1117 1123
6. DA Dyment GC Ebers AD Sadovnick 2004 Genetics of multiple sclerosis Lancet Neurol 3 104 110
7. JB Harley KL Moser PM Gaffney 1998 The genetics of human systemic lupus erythematosus Curr Opin Immunol 10 690 696
8. MC Hung YK Lau 1999 Basic science of HER-2/neu: a review Semin Oncol 26 51 59
9. J Jacob O Radkevich G Forni 2006 Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice Cell Immunol 240 96 106
10. JB Jacob YM Kong C Meroueh 2007 Control of Her-2 tumor immunity and thyroid autoimmunity by MHC and regulatory T cells Cancer Res 67 7020 7027
11. R Kiessling WZ Wei F Herrmann 2002 Cellular immunity to the Her-2/neu protooncogene Adv Cancer Res 85 101 144
12. BL King D Carter HG Foellmer 1992 Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines Am J Pathol 140 23 31
13. YM Kong LC Lomo RW Motte 1996 HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA-DRB1*0301 (DR3) gene J Exp Med 184 1167 1172
14. KY Lin FG Guarnieri KF Staveley-O'Carroll 1996 Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen Cancer Res 56 21 26
15. KH Mahoney BE Miller GH Heppner 1985 FACS quantitation of leucine aminopeptidase and acid phosphatase on tumor-associated macrophages from metastatic and nonmetastatic mouse mammary tumors J Leukoc Biol 38 573 585
16. RB Montgomery E Makary K Schiffman 2005 Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase Cancer Res 65 650 656
17. P Nanni GL Nicolson C De Giovanni 2001 Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice J Exp Med 194 1195 1205
18. MB Oldstone 2005 Molecular mimicry, microbial infection, and autoimmune disease: evolution of the concept Curr Top Microbiol Immunol 296 1 17
19. MP Piechocki YS Ho S Pilon 2003 Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines J Immunol 171 5787 5794
20. MP Piechocki SA Pilon WZ Wei 2002 Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA J Immunol Methods 259 33 42
21. SA Pilon C Kelly WZ Wei 2003 Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor J Immunol 170 1202 1208
22. SA Pilon MP Piechocki WZ Wei 2001 Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody J Immunol 167 3201 3206
23. RT Reilly MB Gottlieb AM Ercolini 2000 HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice Cancer Res 60 3569 3576
24. EH Romond EA Perez J Bryant 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684
25. S Rovero A Amici ED Carlo 2000 DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice J Immunol 165 5133 5142
26. S Sjogren M Inganas A Lindgren 1998 Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers J Clin Oncol 16 462 469
27. DJ Slamon GM Clark SG Wong 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182
28. DJ Slamon W Godolphin LA Jones 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707 712
29. G Strauss DA Vignali G Schonrich 1994 Negative and positive selection by HLA-DR3(DRw17) molecules in transgenic mice Immunogenetics 40 104 108
30. WZ Wei J Jacob O Radkevich-Brown 2008 The "A, B and C" of Her-2 DNA vaccine development Cancer Immunol Immunother 57 11 1711 1717
31. WZ Wei WP Shi A Galy 1999 Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA Int J Cancer 81 748 754
32. IB Weinstein A Joe D Felsher 2008 Oncogene addiction Cancer Res 68 3077 3080
33. PJ Whittington MP Piechocki HH Heng 2008 DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies Cancer Res 68 18 7502 7511
34. ME Wolpoe ER Lutz AM Ercolini 2003 HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice J Immunol 171 2161 2169
35. FM Yakes W Chinratanalab CA Ritter 2002 Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action Cancer Res 62 4132 4141